Business
Vor Reports Second Quarter 2021 Financial Results and Provides Company Update
On track to report initial VOR33 clinical data in the first half of 2022Announced collaborations with Abound Bio and Janssen to develop novel treatment
About this update from Vor Biopharma Inc.
[{"type":"text","content":"On track to report initial VOR33 clinical data in the first half of 2022Announced collaborations with Abound Bio and Janssen to develop novel treatment systems for hematologic malignanciesInitiated build-out of in-house clinical manufacturing facility CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2021, and provided a business update. “Vor is pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted cancer therapies, and this quarter, we made several important advancements towards the clinic, and expanded our platform as we continue our mission to change the treatment paradigm in oncology,” said Robert Ang, MBBS, MBA, Vor’s President and Chief Executive Officer. “We are making progress in our VOR33 Phase 1/2a trial with site initiation activities well underway and we remain on track to release initial clinical data in the first half of 2022. We are proud to have begun construction on our own manufacturing facility, which is another critical milestone in our journey to develop novel treatment systems for patients facing acute myeloid leukemia and other serious blood cancers.” Corporate Highlights Expect to enroll first patient in VOR33 acute myeloid leukemia (AML) Phase 1/2a clinical trial in the next few months. VOR33 is the Company’s lead product candidate, consisting of CRISPR genome-edited hematopoietic stem and progenitor cells that have been engineered to lack the CD33 protein. It is designed to replace the standard of care in transplant settings for patients suffering from AML and potentially other hematologic malignancies. The primary endpoint assessing the safety of VOR33 is the incidence of successful engraftment at 28 days. The Company remains on track to report initial clinical data in the first half of 2022.Signed collaborations with Abound Bio and Janssen, expanding Vor’s platform to explore additional companion therapy opportunities for eHSCs. A key strategic initiative for Vor is to pair future engineered hematopoietic stem cell (eHSC) product candidates with companion therapeutics beyond VCAR33. In June, the Company entered into a multi-year strategic collaboration with Abound Bio, a biotechnology company generating novel ant...